Achillion's ACH-3422 Shows Compelling Preclinical Profile

Achillion Pharmaceuticals (NASDAQ: ACHN ) today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection (HCV). The poster is being presented at the 64th Annual Meeting of the American Association for the Study